Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1

Interventions

fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 15Cyclophosphamide 15Whole-Body Irradiation 14Tacrolimus 13Mycophenolic Acid 13Busulfan 12Antilymphocyte Serum 11Rituximab 9Etoposide 7Methotrexate 6Cyclosporine 6Melphalan 5thymoglobulin 4Flow Cytometry 4Carboplatin 4Therapeutics 3Radiotherapy 3Lenalidomide 3In Situ Hybridization, Fluorescence 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Everolimus 3Amplified Fragment Length Polymorphism Analysis 3Alemtuzumab 3fludarabine 2Vorinostat 2Vincristine 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Extranodal NK-T-Cell × siplizumab × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡